224 related articles for article (PubMed ID: 28278725)
1. Intravascular large B-cell lymphoma in the United States (US): a population-based study using Surveillance, Epidemiology, and End Results program and National Cancer Database.
Rajyaguru DJ; Bhaskar C; Borgert AJ; Smith A; Parsons B
Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28278725
[TBL] [Abstract][Full Text] [Related]
2. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab.
Gundrum JD; Mathiason MA; Moore DB; Go RS
J Clin Oncol; 2009 Nov; 27(31):5227-32. PubMed ID: 19770371
[TBL] [Abstract][Full Text] [Related]
3. Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database.
Bhatt VR; Giri S; Verma V; Manandhar S; Pathak R; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):373-8. PubMed ID: 27349764
[TBL] [Abstract][Full Text] [Related]
4. A comparative population-based analysis of sinonasal diffuse large B-cell and extranodal NK/T-cell lymphomas.
Dubal PM; Dutta R; Vazquez A; Patel TD; Baredes S; Eloy JA
Laryngoscope; 2015 May; 125(5):1077-83. PubMed ID: 25546466
[TBL] [Abstract][Full Text] [Related]
5. Diffuse large B-cell lymphoma (DLBCL) with significant intravascular invasion. Close resemblance of its clinicopathological features to intravascular large B-cell lymphoma, but not to DLBCL-not otherwise specified.
Itami H; Nakamine H; Kubo M; Ogawa K; Tani R; Nakamura S; Takeda M; Nitta Y; Uchiyama T; Fujii T; Hatakeyama K; Ohbayashi C
J Clin Exp Hematop; 2021 Sep; 61(3):152-161. PubMed ID: 34193753
[TBL] [Abstract][Full Text] [Related]
6. Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
Shah BK; Bista A; Shafii B
Anticancer Res; 2014 Sep; 34(9):5117-20. PubMed ID: 25202101
[TBL] [Abstract][Full Text] [Related]
7. The incidence and survival outcomes of patients with primary cardiac lymphoma: A SEER-based analysis.
Xiao M; Lin J; Xiao T; Lin Y; Ye Y
Hematol Oncol; 2020 Aug; 38(3):334-343. PubMed ID: 32311106
[TBL] [Abstract][Full Text] [Related]
8. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.
Castillo JJ; Winer ES; Olszewski AJ
Am J Hematol; 2014 Mar; 89(3):310-4. PubMed ID: 24273125
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.
Suzuki Y; Kohno K; Matsue K; Sakakibara A; Ishikawa E; Shimada S; Shimada K; Mabuchi S; Takahara T; Kato S; Nakamura S; Satou A
Cancer Med; 2020 Jul; 9(13):4768-4776. PubMed ID: 32367674
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular mortality among patients with non-Hodgkin lymphoma: Differences according to lymphoma subtype.
Abuamsha H; Kadri AN; Hernandez AV
Hematol Oncol; 2019 Aug; 37(3):261-269. PubMed ID: 30916804
[TBL] [Abstract][Full Text] [Related]
11. Epidemiologic, prognostic, and treatment factors in sinonasal diffuse large B -cell lymphoma.
Varelas AN; Eggerstedt M; Ganti A; Tajudeen BA
Laryngoscope; 2019 Jun; 129(6):1259-1264. PubMed ID: 30570148
[TBL] [Abstract][Full Text] [Related]
12. Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases.
Graff-Baker A; Roman SA; Thomas DC; Udelsman R; Sosa JA
Surgery; 2009 Dec; 146(6):1105-15. PubMed ID: 19958938
[TBL] [Abstract][Full Text] [Related]
13. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States.
Shenoy PJ; Malik N; Nooka A; Sinha R; Ward KC; Brawley OW; Lipscomb J; Flowers CR
Cancer; 2011 Jun; 117(11):2530-40. PubMed ID: 24048801
[TBL] [Abstract][Full Text] [Related]
14. Racial differences in three major NHL subtypes: descriptive epidemiology.
Li Y; Wang Y; Wang Z; Yi D; Ma S
Cancer Epidemiol; 2015 Feb; 39(1):8-13. PubMed ID: 25560974
[TBL] [Abstract][Full Text] [Related]
15. Primary Urinary Tract Lymphoma: Rare but Aggressive.
Lontos K; Tsagianni A; Msaouel P; Appleman LJ; Nasioudis D
Anticancer Res; 2017 Dec; 37(12):6989-6995. PubMed ID: 29187485
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and outcomes of primary adrenal diffuse large B cell lymphoma in a large contemporary cohort: a SEER-based analysis.
Li S; Wang Z; Wu Z; Zhuang H; Xu Y
Ann Hematol; 2019 Sep; 98(9):2111-2119. PubMed ID: 31227873
[TBL] [Abstract][Full Text] [Related]
17. Unstaged Diffuse Large B-Cell Lymphoma in the United States: Predictors and Patient Outcomes.
Bista A; Sharma S; Rijwani T; Shah BK
Anticancer Res; 2017 Apr; 37(4):1935-1939. PubMed ID: 28373463
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
Hamlin PA; Satram-Hoang S; Reyes C; Hoang KQ; Guduru SR; Skettino S
Oncologist; 2014 Dec; 19(12):1249-57. PubMed ID: 25342313
[TBL] [Abstract][Full Text] [Related]
19. Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends.
Howlader N; Morton LM; Feuer EJ; Besson C; Engels EA
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):174-9. PubMed ID: 26472423
[TBL] [Abstract][Full Text] [Related]
20. Older patients with early-stage diffuse large B-cell lymphoma: the role of consolidation radiotherapy after chemoimmunotherapy.
Parikh RR; Yahalom J
Leuk Lymphoma; 2017 Mar; 58(3):614-622. PubMed ID: 27685446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
